Finance

Lists
Why is CRSP down 3.47%?
Dive Deeper
CRSP:NASDAQ
Crispr Therapeutics AG
$51.54
-3.47%
(-1.85) 1D
Oct 12, 2:06:33 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRSP...
Open
$52.91
High
$53.21
Low
$51.44
Mkt. cap
4.97B
Avg. vol.
1.63M
Volume
517.46K
52-wk high
$75.16
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
Open
$52.91
High
$53.21
Low
$51.44
Mkt. cap
4.97B
Avg. vol.
1.63M
Volume
517.46K
52-wk high
$75.16
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
News stories
From web sources and news partners
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitecrisprtx.com
Analyst ratings
Based on 13 analysts giving stock ratings to CRSP in the past 3 months
Buy
Buy
8
Hold
5
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for CRSP in the last 3 months.
Highest
Current $51.54
$110.00 (+113.45%)
Average
$73.50 (+42.62%)
Lowest
$45.00 (-12.68%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Buy
Maintained
$81.00
+57.2%
10/09/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$80.00
+55.2%
10/09/2026
Gil Blum
Needham
Buy
Maintained
$82.00
+59.1%
10/05/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
$75.00
+45.5%
10/02/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$88.00
+70.8%
09/04/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$76.00
+47.5%
08/31/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/28/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
$60.00
+16.4%
08/28/2026
Salveen Richter
Goldman Sachs
Hold
Reiterated
$55.00
+6.7%
08/10/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
$55.00
+6.7%
08/06/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$60.00
+16.4%
08/04/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$110.00
+113.4%
08/04/2026
Tyler Van Buren
TD Cowen
Hold
Maintained
$45.00
-12.7%
08/03/2026
Luca Issi
RBC Capital
Hold
Maintained
$50.00
-3%
08/03/2026
Silvan Turkcan
Citizens JMP
Buy
Maintained
$80.00
+55.2%
07/22/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$85.00
+64.9%
06/10/2026
William Pickering
Bernstein
Hold
Reiterated
$56.00
+8.7%
05/13/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$76.00
+47.5%
05/04/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/02/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$67.00
+30%
02/13/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
$80.00
+55.2%
01/30/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
889.00K
864.00K
1.46M
10.18M
Cost of goods sold
116.02M
137.23M
114.52M
107.42M
Cost of revenue
116.02M
137.23M
114.52M
107.42M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.93M
18.40M
17.18M
17.55M
Operating expense
16.93M
18.40M
17.18M
17.55M
Total operating expenses
132.95M
155.63M
131.71M
124.98M
Operating income
-132.06M
-154.76M
-130.25M
-114.80M
Other non operating income
26.24M
24.76M
8.16M
27.08M
EBT including unusual items
-105.82M
-130.00M
-122.09M
-90.19M
EBT excluding unusual items
-105.82M
-130.00M
-122.09M
-87.72M
Income tax expense
619.00K
614.00K
839.00K
960.00K
Effective tax rate
-0.58%
-0.47%
-0.69%
-1.06%
Other operating expenses
-
-
-
-
Net income
-106.44M
-130.61M
-122.93M
-91.15M
Net profit margin
-11,973.12%
-15,117.25%
-8,431.48%
-895.33%
Earnings per share
-1.17
-1.37
-1.28
-0.94
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-127.63M
-149.10M
-125.93M
-110.52M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps